title: Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage.
authors.forename: Andrea
authors.initials: A
authors.lastname: Calcagno
authors.forename: Stefano
authors.initials: S
authors.lastname: Bonora
authors.forename: Marco
authors.initials: M
authors.lastname: Simiele
authors.forename: Roberto
authors.initials: R
authors.lastname: Rostagno
authors.forename: Maria C
authors.initials: MC
authors.lastname: Tettoni
authors.forename: Marino
authors.initials: M
authors.lastname: Bonasso
authors.forename: Alessandra
authors.initials: A
authors.lastname: Romito
authors.forename: Daniele
authors.initials: D
authors.lastname: Imperiale
authors.forename: Antonio
authors.initials: A
authors.lastname: D'Avolio
authors.forename: Giovanni
authors.initials: G
authors.lastname: Di Perri
mesh_terms: D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000328:Adult; D001812:Blood-Brain Barrier / Q000187:drug effects* / Q000293:injuries; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000068679:Emtricitabine; D005260:Female; D015658:HIV Infections / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000009:adverse effects*; D010865:Pilot Projects; D000068698:Tenofovir
chemical_list: D063065:Organophosphonates; D003841:Deoxycytidine; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine